Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Pyridoxine Hydrochloride

FDA-approved product (injectable, injection), marketed as Hexa-Betalin, Pyridoxine Hydrochloride.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
0 of 4

Chemical structure

Chemical structure of Pyridoxine Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Anemia
  • Anemia (phenotype)
  • Chronic kidney disease
  • Folate deficiency
  • Iron deficiency anemia
  • Nausea and vomiting
  • Osteoporosis
  • Type 2 diabetes mellitus

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other plain vitamin preparations
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

No supported pathogen reaches ≥40% AI-predicted activity for Pyridoxine Hydrochloride, so it is not among the repurposing candidates. Its predictions are shown below.

AI-predicted activity

AI prediction · nothing measured
  • MRSA27.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli23.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae12.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis14.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Pyridoxine Hydrochloride in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Pyridoxine Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Effects of Bromelain and Boswellia Serrata Casperome With Centella Asiatica and Vitamins on Edema, Paresthesia and Postoperative Pain After Quadrantectomy With or Without Sentinel Lymph Node Biopsy.

    NCT04669119 · start 2020-12-31

    Registered record
    Registry ID
    NCT04669119
    Conditions
    Breast Cancer Female; Pain, Postoperative
    Interventions
    Bromelain/Boswellia Serrata Casperome; Centella Asiatica/Vitamins; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2020-12-31
    Completion
    2022-01-31
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer Female; Pain, Postoperative
    InterventionBromelain/Boswellia Serrata Casperome; Centella Asiatica/Vitamins; Placebo
    PhasePhase 4
    Registry statusUnknown

  • The Benefits of Vitamin B Combination as Add on Therapy in the Management of Painful Diabetic Neuropathy Patient

    NCT04689971 · start 2020-11-03

    Registered record
    Registry ID
    NCT04689971
    Conditions
    Painful Diabetic Neuropathy
    Interventions
    Standard therapy; Vitamin B combination
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Unknown
    Start
    2020-11-03
    Completion
    2021-11
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPainful Diabetic Neuropathy
    InterventionStandard therapy; Vitamin B combination
    PhasePhase 2 / Phase 3
    Registry statusUnknown

  • Revascularization of Stenosed Vessels Using Optimized Treatment of Rejuveinix for Reversing Endothelial Dysfunction

    NCT03041259 · start 2020-01

    Registered record
    Registry ID
    NCT03041259
    Conditions
    Critical Limb Ischemia; Peripheral Arterial Disease
    Interventions
    Rejuveinix Low Dose; Rejuveinix High Dose
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Unknown
    Start
    2020-01
    Completion
    2022-07
    Enrolment
    320

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCritical Limb Ischemia; Peripheral Arterial Disease
    InterventionRejuveinix Low Dose; Rejuveinix High Dose
    PhasePhase 1 / Phase 2
    Registry statusUnknown

  • Effect of a Fortified Balanced Energy-Protein Supplement on Birth Outcome and Child Growth in Houndé District, Burkina Faso.

    NCT03533712 · start 2019-10-30

    Registered record
    Registry ID
    NCT03533712
    Conditions
    Small for Gestational Age at Delivery; Low Birth Weight; Prematurity; Infant Malnutrition
    Interventions
    Fortified balanced energy-protein (BEP) supplement; Fe and folic acid supplement
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2019-10-30
    Completion
    2022-03-15
    Enrolment
    1,788

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSmall for Gestational Age at Delivery; Low Birth Weight; Prematurity; Infant Malnutrition
    InterventionFortified balanced energy-protein (BEP) supplement; Fe and folic acid supplement
    PhasePhase 4
    Registry statusCompleted

  • Tuberculosis Preventive Therapy Among Latent Tuberculosis Infection in HIV-infected Individuals

    NCT03785106 · start 2019-08-15

    Registered record
    Registry ID
    NCT03785106
    Conditions
    HIV-infected Participants With Latent TB Infection in High TB Burden Country
    Interventions
    Isoniazid/Rifapentine daily (4 weeks) plus pyridoxine (vitamin B6); Isoniazid/Rifapentine 12-weekly plus pyridoxine (vitamin B6)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2019-08-15
    Completion
    2038-03
    Enrolment
    2,500

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-infected Participants With Latent TB Infection in High TB Burden Country
    InterventionIsoniazid/Rifapentine daily (4 weeks) plus pyridoxine (vitamin B6); Isoniazid/Rifapentine 12-weekly plus pyridoxine (vitamin B6)
    PhasePhase 3
    Registry statusActive not recruiting

  • A Study to Investigate Differences in the Extent and Rate of Absorption of Doxylamine/Pyridoxine From 2 Different Products Under Fasting Conditions

    NCT03905564 · start 2019-06

    Registered record
    Registry ID
    NCT03905564
    Conditions
    Bioavailability
    Interventions
    doxylamine succinate 10 mg/pyridoxine hydrochloride 10 mg combination; Diclegis (Registered Trademark)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Withdrawn
    Start
    2019-06
    Completion
    2020-06
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBioavailability
    Interventiondoxylamine succinate 10 mg/pyridoxine hydrochloride 10 mg combination; Diclegis (Registered Trademark)
    PhasePhase 1
    Registry statusWithdrawn

  • Trial to Assess Chelation Therapy in Critical Limb Ischemia

    NCT03982693 · start 2019-03-19

    Registered record
    Registry ID
    NCT03982693
    Conditions
    Critical Limb Ischemia; Diabetes
    Interventions
    Edetate Disodium; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2019-03-19
    Completion
    2027-07
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCritical Limb Ischemia; Diabetes
    InterventionEdetate Disodium; Placebo
    PhasePhase 3
    Registry statusActive not recruiting

  • Nitric Oxide Donor Isosorbide Mono Nitrate for Induction of Labor With Pre-labor Rupture of Membranes

    NCT03665779 · start 2018-08-01

    Registered record
    Registry ID
    NCT03665779
    Conditions
    Induction of Labor Affected Fetus / Newborn; Rupture of Membranes Prior to Onset of Labor
    Interventions
    isosorbide mononitrate; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2018-08-01
    Completion
    2019-05-01
    Enrolment
    140

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInduction of Labor Affected Fetus / Newborn; Rupture of Membranes Prior to Onset of Labor
    Interventionisosorbide mononitrate; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Evaluate the Neuroprotective Effect of Vitamin B6 and Vitamin B12 Against Vincristine Induced Neurotoxicity in Acute Lymphoblastic Leukaemia Patients

    NCT03593304 · start 2018-03-29

    Registered record
    Registry ID
    NCT03593304
    Conditions
    Vincristine Induced Neurotoxicity; Acute Lymphoblastic Leukaemia
    Interventions
    Injection Mecobalamin; Tablet Pyridoxine hydrochlorid; Normal saline; Oral Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2018-03-29
    Completion
    2019-03-30
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVincristine Induced Neurotoxicity; Acute Lymphoblastic Leukaemia
    InterventionInjection Mecobalamin; Tablet Pyridoxine hydrochlorid; Normal saline; Oral Placebo
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Absorption of Transdermal Vitamins in Post Bariatric Surgery Patients

    NCT03360435 · start 2017-12-15

    Registered record
    Registry ID
    NCT03360435
    Conditions
    Bariatric Surgery Candidate; Vitamin Deficiency; Mineral Deficiency
    Interventions
    Patch MD MultiVitamin Plus patch
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2017-12-15
    Completion
    2021-07-07
    Enrolment
    99

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBariatric Surgery Candidate; Vitamin Deficiency; Mineral Deficiency
    InterventionPatch MD MultiVitamin Plus patch
    PhaseNot recorded
    Registry statusCompleted

  • Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Lymphoma

    NCT02961816 · start 2017-06

    Registered record
    Registry ID
    NCT02961816
    Conditions
    Lymphoma
    Interventions
    Palifermin; Panobinostat; Gemcitabine; Busulfan; Melphalan; Rituximab; Dexamethasone; Caphosol; Glutamine; Oral Cryotherapy (ice chips); Pyridoxine; Stem Cell Infusion; G-CSF
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2017-06
    Completion
    2021-06
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLymphoma
    InterventionPalifermin; Panobinostat; Gemcitabine; Busulfan +9 more
    PhasePhase 2
    Registry statusWithdrawn

  • The Effects of a Combination of Nootropic Ingredients on Cognition in Healthy Young Volunteers

    NCT02857829 · start 2017-03-01

    Registered record
    Registry ID
    NCT02857829
    Conditions
    Biomedical Enhancement
    Interventions
    CAF+; Caffeine-alone; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2017-03-01
    Completion
    2017-03-24
    Enrolment
    21

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBiomedical Enhancement
    InterventionCAF+; Caffeine-alone; Placebo
    PhaseNot applicable
    Registry statusCompleted

  • Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype

    NCT02589145 · start 2016-06-22

    Registered record
    Registry ID
    NCT02589145
    Conditions
    Lymphoma
    Interventions
    Lenalidomide; Vorinostat; Gemcitabine; Busulfan; Melphalan; Rituximab; Dexamethasone; Caphosol; Glutamine; Pyridoxine; Enoxaparin; Stem Cell Transplant; Palifermin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Terminated
    Start
    2016-06-22
    Completion
    2019-04-08
    Enrolment
    8

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLymphoma
    InterventionLenalidomide; Vorinostat; Gemcitabine; Busulfan +9 more
    PhasePhase 1 / Phase 2
    Registry statusTerminated

  • TBTC Study 31: Rifapentine-containing Tuberculosis Treatment Shortening Regimens

    NCT02410772 · start 2016-01-25

    Registered record
    Registry ID
    NCT02410772
    Conditions
    Tuberculosis
    Interventions
    rifapentine; rifapentine and moxifloxacin; control
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2016-01-25
    Completion
    2021-05
    Enrolment
    2,516

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis
    Interventionrifapentine; rifapentine and moxifloxacin; control
    PhasePhase 3
    Registry statusCompleted

  • Pharmacokinetic and Pharmacodynamic Study of High-Dose Rifapentine and Moxifloxacin for Treatment of Tuberculosis

    NCT02563327 · start 2016-01-25

    Registered record
    Registry ID
    NCT02563327
    Conditions
    Tuberculosis
    Interventions
    Rifapentine; Moxifloxacin; Rifampin; Isoniazid; Pyrazinamide; Ethambutol; Pyridoxine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2016-01-25
    Completion
    2021-08-30
    Enrolment
    2,516

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis
    InterventionRifapentine; Moxifloxacin; Rifampin; Isoniazid +3 more
    PhasePhase 3
    Registry statusCompleted